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Inactivation of tumour suppressor genes plays an important role in
human cancer formation and progression. The distal short arm
of chromosome 1 or 1p36 is thought to harbour several tumour
suppressor genes because loss of heterozygosity (LOH) in this
region is common in a large number of different types of human
cancers (Weith et al, 1996). One candidate in this region is the
retinoblastoma protein-interacting zinc finger gene RIZ(PRDM2),
which was isolated in a functional screening for Rb-binding proteins
(Buyse et al, 1995), also independently isolated as a DNA-binding
protein MTB-Zf (Muraosa et al, 1996), a GATA3 transcription
factor binding protein G3B (Shapiro et al, 1995), and a coactivator
of oestrogen receptor (ER) (Abbondanza et al, 2000). The gene
maps within the minimal deleted region on 1p36 in liver, breast and
familial colon cancers (Chadwick et al, 2000; Fang et al, 2000). 
RIZ is a member of a gene family which shares a ~ 130 amino
acid motif called the PR (PRDI-BF1 and RIZ) domain, also termed
SET (Suvar3-9,  Enhancer-of-zeste,  Trithorax); the family is
known to play an important role in chromatin-mediated gene
expression, development and cancer (Huang et al, 1998). The
PR/SET domain shows significant homology with plant protein
lysine methyltransferase (MTase); the PR/SET domain of
SUV39H1 can methylate histone H3 and plays an important role
in chromatin condensation during mitosis (Rea et al, 2000). The
PR/SET domain represents the catalytic core motif and appears to
define a large family of protein lysine methyltransferases. 
The RIZ gene produces 2 products through alternative promoters,
RIZ1 that contains the PR domain and RIZ2 lacking the motif (Liu
et al, 1997). Decreased or lost expression of RIZ1 mRNA but not of
RIZ2 is found in all human cancers examined, including those of
breast, liver, lung, colon, and neuroendocrine tissues, suggesting a
tumour suppressor role for the RIZ1 product (He et al, 1998;
Jiang et al, 1999; Chadwick et al, 2000). In addition, frequent frame
shift mutations of RIZ appear selected in gastrointestinal, endomet-
rial, and pancreatic tumours associated with microsatellite insta-
bility (Chadwick et al, 2000; Piao et al, 2000; Sakurada et al, 2001).
Together, these findings show frequent inactivation of RIZ1 in a
broad spectrum of human cancers. Consistently, recombinant aden-
ovirus-mediated RIZ1 expression can induce G2/M cell cycle
arrest, apoptosis, or both in several tumour cell lines (He et al, 1998;
Jiang et al, 1999; Chadwick et al, 2000). 
To further determine the role of RIZin HCC and other 1p36-linked
human cancers, we here studied RIZ gene mutations and LOH in
HCC, breast cancer, familial melanoma, colon cancer and stomach
cancer. The previously described Pro704-deletion polymorphism
(Fang et al, 2000) was analysed for its potential differential involve-
ment in carcinogenesis. The distribution of this polymorphism in
Asian and Caucasian populations were also determined. 
MATERIALS AND METHODS 
Tissue DNAs 
Blood DNAs of 6 patients from 6 different melanoma families
were examined for peptide-altering mutations in the entire coding
region of RIZ1 by SSCP analysis. The identification numbers
of these DNAs were 7559206, 3234202, 0720200, 5864201,
0617200, and 0099204. These DNAs have been described pre-
viously (Bale et al, 1989). 
147 HCC cases were included in the study. Among these, 39
were collected at the Yonsei University Medical Center, Seoul,
Preferential loss of a polymorphic RIZ allele in human
hepatocellular carcinoma 
W Fang1, Z Piao1, IM Buyse1#, D Simon2, JC Sheu3, M Perucho1 and S Huang1
1Program in Oncogenes and Tumor Suppressor Genes, The Burnham Institute, La Jolla, CA 92037; 2Department of Pathology, MCP-Hahnemann School of
Medicine, Philadelphia, PA 19109; 3Department of Internal Medicine, National Taiwan University Hospital, No. 1, Chang-Te street, Taipei, Taiwan 
Summary The RIZ (PRDM2) locus commonly undergoes loss of heterozygosity (LOH) and maps within the minimal deleted region on 1p36
in hepatocellular carcinoma (HCC). Although peptide-altering mutations of RIZ are rare in HCC, the RIZ1 product is commonly lost in HCC
and has tumour suppressive activities. Here, we analysed RIZ gene mutations and LOH in HCC, breast cancer, familial melanoma, colon
cancer, and stomach cancer. We found 7 polymorphisms but no mutations. By analysing the Pro704-deletion polymorphism, we detected
LOH of RIZ in 31 of 79 (39%) informative HCC cases, 11 of 47 (23%) colon cancer cases, 8 of 43 (19%) breast cancer cases, 8 of 66 (12%)
stomach cancer cases. Importantly, loss of the Pro704+ allele was found in 74% of the 31 LOH positive HCC cases (P < 0.01), indicating a
preferential loss and hence a stronger tumour suppressor role for this allele compared to the P7042 allele. In addition, the Pro704+ allele was
found to be more common in Asians (0.61) than Caucasians (0.42) (P= 0.0000), suggesting an interesting link between gene polymorphisms
and potential differences in tumour incidence between racial groups. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: RIZ (PRDM2); polymorphisms; hepatoma 
743
Received 21 June 2000 
Revised 20 November 2000 
Accepted 29 November 2000 
Correspondence to: S Huang 
British Journal of Cancer (2001) 84(6), 743–747
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1667, available online at http://www.idealibrary.com on 
#Present address: Department of Molecular and Human Genetics, Baylor DNA
Diagnostic Laboratory, Baylor College of Medicine, One Baylor Plaza, Houston,
TX77030. 
http://www.bjcancer.comKorea, which have been described previously (Piao et al, 1998a,
1998b); 10 were collected at the University of Miami and
University of Pittsburgh, which have been described in Hammond
et al (1999) and (Simon et al 1991); 98 were collected at the
National Taiwan University Hospital, which have been described
in (Lin et al, 1999). 
40 breast cancer cases, 46 primary colon cancer cases, and 86
stomach cancer cases were also included in this study which were
collected at the Yonsei University Medical Center, Seoul, Korea.
In addition, 60 colon cancer cases, 39 stomach cancer cases, and
41 breast cancer cases were obtained from the Connective Tissue
Network at the University of Alabama; the DNA from these
tumours and their adjacent non-tumoral tissues were extracted
using standard procedures. 
DNAs from 30 normal Caucasian individuals were collected at
the University of Leuven, Belgium. In addition, DNAs from 13
normal Caucasian individuals were collected at McGill University,
Montreal, Quebec (kind gift of Dr C Polychronakos of McGill
University). 
SSCP, allelotyping, and DNA sequencing analysis 
PCR primers for SSCP analysis of the PR domain region of RIZ1
including exons 2–7 were described previously. PCR primers for
the remaining part of RIZ1 gene including exons 8–9 are listed in
Table 1. PCR reactions were carried out in a mixture of 20 ml
containing 1.5 mM MgCl2, 20 pmol primer, 0.2 mM each dATP,
dGTP, dTTP, 5 mM dCTP, 1 mCi a-32P-dCTP (3000 Ci mmol-1;
NEN DuPont, Boston, MA), 25 ng of sample DNA, 1X PCR
buffer and 1.25 U Taq polymerase. After denaturation at 95˚C for
4 min, DNA amplification was performed in 25–30 cycles
consisting of denaturation at 95˚C for 30 s, primer annealing at
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Table 1 PCR primers for SSCP analysis of RIZ gene 
Primers Coordinatesa Sequences (5¢ to 3¢) 
RP111b intron 8 (622) CTT CTG CTT CCA TGT GCT 
RP112 888 CCC TCG TCT TCC AAC TC 
RP110c 891 AGA AGA AGC CAG CAT GCC 
RP142 1455 GCA CGG ATG AAG TTC TTT AA 
RP143c 1413 GTC GTA GAA GAG AAT GGG 
RP118 2008 CTC ACT ATT TGT GCT GCC 
RP144 1888 GGC AGC ACA AAT AGT GAG 
RP105 2358 ACT CCA TGC TGG TGA GTC 
RP29c 2349 AGC ATG GAG TTT GTC TG 
RP124 2828 GGT GTG GAC TCA ACA GT 
RP88 2771 AGA TCC TGA CCT CGG TC 
RP125 3056 GAC TGT GCG GTG GCA T 
RP90 2998 CTT CCA GTG CAT CTC CAC A 
RP92 3341 CTG GGT TTC AGA CCT TCA 
RP91 3357 TGC TGC TGC ACA GGA TGT 
RP126 3635 CGC TGG TGC TGC TGC A 
RP127 3569 ATC TTT GTG TGT TCT GT 
RP51 3817 TCG TGT AAA GCT CTT CAG 
RP128 3780 GAG GAG TTA AAT GAT TC 
RP140 4089 CTT CTT GTC ACT TGC AGA 
RP129 4024 GGT GTC GAC AAT ATG CC 
RP130 4298 GCT TTC TGT ACT AGC TG 
RP132 4237 TGT CGT CGA ATA AGC TC 
RP146 4499 TGT CCA CCT TTC TTA GA 
RP134 4423 GCC GCC TTC AGC TGT CC 
RP107 4670 TTC TGC TTG GAC CTG AAG 
RP135 4593 TTG GGC AAG ACC AGA GC 
RP147 4812 AAG CTG AGC AGA ATG A 
RP60 4734 CCG ATA AGA ATG GCC AAA 
RP137 intron (5039) CCC ACC AGC TCC TGA GC 
RP95 5039 CTA CAG CCT CCG CTT GGC G
RP100 5174 AGC AGC CAG AGT GTC TA 
aThe first nucleotide of the human RIZ1 cDNA coding region is designated 1. bThese primers are located within introns; the positions
of the exon boundaries are listed in brackets. cThe PCR product of RP110+RP142 was digested with Nsil before SSCP gel analysis.
The PCR product of RP143+RP118 was digested with Hapll before SSCP gel analysis. The PCR product of RP29+RP134 was
digested with EcoRI before SSCP gel analysis. 55–60˚C for 30 s, and elongation at 72˚C for 30 s. GC-melt kit
(Clontech, CA) was used to PCR the GC rich exon 6. Amplified
DNA was diluted 2-fold with stop solution (95% formamide,
20 mM EDTA, 0.05% xylene cyanol and 0.05% bromophenol
blue). 3 microlitres of amplified product were loaded onto MDE
gel (FMC BioProducts, Rockland, ME 04841) for SSCP analysis
or 6% polyacrylamide gel containing 5.6 M urea. For some PCR
products, restriction digestion was performed before loading. The
gel was dried on filter paper and exposed to Kodak XAR-5 film.
Allelic loss was scored when band intensity of one allelic marker
was significantly decreased (more than 70% reduction) in tumour
DNA as compared with that in normal DNA. All variants detected
by SSCP analysis were confirmed by DNA sequencing analysis. 
Statistical analysis 
We correlate the LOH frequency with several clinical aspects,
including sex, age, tumour size, and status of hepatitis B or C virus
infection. The statistical analysis was performed by the computer
program STATISTICA (StatSoft, Tulsa, OK, USA). The P values
were obtained by Chi-square test. 
RESULTS 
Lack of peptide altering mutations in RIZ1 in familial
melanoma and breast cancers 
A locus for familial cutaneous malignant melanoma-dysplastic
naevus has been mapped to the region between an anonymous DNA
marker (D1S47) and the gene locus for pronatrodilatin (NPPA) (Bale
et al, 1989). To determine whether familial malanoma may carry
peptide altering mutations in RIZ which maps just distal to NPPA,
we performed SSCP analysis of DNAs from 6 familial melanoma
patients. We did not detect mutations in the entire coding region of
RIZ1 but found several polymorphic alleles of RIZ as shown in
Table 2. 4 of these were silent nucleotide substitutions without
affecting amino acid sequences. 2 were amino-acid substitutions,
D283E and S450N. One was a deletion of a proline at codon 704 that
has previously been described (Fang et al, 2000). We also scanned
the PR domain region of RIZ1 in 61 breast cancer cases by SSCP
analysis. We did not find any mutations besides the polymorphisms. 
LOH of RIZ in human cancers and preferential deletion
of the Pro704+ allele in HCC 
Because of the relatively high rate of heterozygosity of the
Pro704-deletion polymorphism (~50%), we used it to study
whether LOH at the RIZ locus may be common in human cancers.
We were also interested to determine whether this polymorphism
may show differential linkage with human cancers. A total of 459
tumour cases were analysed and 235 of these were heterozygous
for Pro704-deletion polymorphism as shown in Table 3. The
tumours studied included HCC, breast cancer, colon cancer and
stomach cancer. 58 of the 235 (25%) informative cases showed
LOH at the RIZ locus. LOH was most common in HCC (31 of 79
or 39%), followed by colon carcinoma (11 of 47 or 23%), breast
cancer (8 of 43 or 19%), and stomach cancer (8 of 66 or 12%).
LOH of RIZ appeared more common in metastatic colon cancer
(3/7) than primary colon carcinoma 8/40, but there was no statist-
ical significance. No significant association of RIZ LOH with any
clinical parameters of these tumours was observed, 
Notably, the Pro704+ allele was lost in 74% of the 31 LOH-
positive HCC cases, indicating a significant preferential loss of
this allele compared to the Pro704- allele (P < 0.01) (Figure 1).
This preferential loss of Pro704+ allele did not correlate with any
clinical parameters of HCC, including gender, age, tumour size,
serum a-fetoprotein, and status of hepatitis B or C virus infection.
A larger sample size will be needed to determine whether prefer-
ential loss of Pro704+ allele was also significant in breast cancer
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Table 2 RIZ polymorphic variants
Variant forms PCR primers Het frequency 
R100 (CGA) to R100 (CGG) RP257 NDa
RP258
D283 (GAT) to E283 (GAA) RP111 35.7% (n = 28) 
RP112
H364 (CAT) to H364 (CAC) RP110 37.5% (n = 8) 
RP142
S450 (AGT) to N450 (AAT) RP110 12.5% (n = 8) 
RP142
P704 (CCT) deletion RP145 50.8% (n = 502) 
RP105
S1609 (TCG) to S1609 (TCA) RP60 37.5% (n = 8) 
RP137
P1707 (CCG) to P1707 (CCA) RP95 N.D. 
RP100
aND = not determined. 
Table 3 LOH of RIZ locus in human cancers 
P704+ del. P704- del. LOH rate 
HCC 23 8 (P < 0.01) 31/79 (39%) 
Colon cancer 6 5 11/47 (23%) 
Breast cancer 5 3 8/43 (19%) 
Stomach cancer 5 3 8/66 (12%) 
Total 39 19 58/235(25%) 
1234567
NC NC NC NC NC NC NC
Fig. 1 Preferential loss of P704+ allele in human HCC. Representative
autoradiographs of LOH analysis of the Pro704-deletion polymorphism. The
HCC (C) and matched non-tumour tissue (N) are shown with case numbers
indicated on the top. Tumour cases 5–7 showed loss of the upper band
representing the P704+ allele. 
Table 4 Distribution of the Pro704-deletion polymorphism in Korean HCC
and non-HCC patients 
P704+ hom P704- hom Het Total P704- freq 
HCCa 11 7 21 39 0.449 
non-HCCa 64 21 87 172 0.375 
aGenomic DNAs of normal tissues from cancer patients were used for the
study. (63% of 8 LOH positive cases), stomach cancer (63% of 8 LOH
positive cases), and colon cancer (55% of 11 LOH positive cases). 
Given the differential involvement of the Pro704-deletion poly-
morphism with HCC, we next asked whether the Pro704- allele
may be more enriched in HCC patients relative to non-HCC
patients. Because different racial groups showed different allele
frequency (see below), we limited our analysis to Korean patients.
The Pro704- allele frequency in Korean HCC patients (0.449) was
higher than that in non-HCC patients (0.375) (Table 4). But, this
was not statistically significant (P = 0.23). 
Distribution of the Pro704-deletion polymorphism in
Caucasian and Asian populations 
Analysis of DNAs from non-tumour tissues of 150 Caucasian
cancer patients from America showed that Pro704+ allele (0.43) was
less common than the Pro704- allele (Table 5). This allele frequency
was found to be similar among different groups of patients with
different cancers, indicating no preferential association of this
allele with any specific type of cancers. 43 normal Caucasians from
Canada and Belgium were also analysed and the Pro704+ allele
(0.36) was again less common. The results did not show significant
variation between Caucasian normal and patient populations in the
distribution of the Pro704-deletion polymorphism. 
The distribution of the Pro704-deletion polymorphism was
studied in 309 Asian cancer patients using their normal tissue
DNAs. The Pro704+ allele was the more common allele (0.61).
This is significantly different from Caucasian cancer patient or
normal populations (P = 0.0000). 
DISCUSSION 
The RIZ1 product of the RIZ locus on 1p36 has been suggested as
a candidate tumour suppressor. Although it maps within the region
thought to harbour the familial melanoma locus, our data here
suggest that peptide-altering mutations in RIZ may not be common
in familial melanoma. Whether other types of RIZ alterations may
be involved in this disease remains to be investigated. 
We showed that LOH of RIZ was common but that peptide-
altering mutations in RIZ1 were rare in breast cancers. The
apparent selection for RIZ2 expression in breast cancers may have
favoured the strategy of RIZ1 gene silencing rather than altering
RIZ1 peptide sequences. This is similar to previous findings of
lack of RIZ1 mutations in HCC where RIZ2 expression is
uniformly present (Jiang et al, 1999; Fang et al, 2000). These
observations suggest that decreasing RIZ1 expression may rep-
resent the more common way of inactivating RIZ1, at least in
breast cancer and HCC. Recent data suggest that decreased RIZ1
expression was through DNA methylation of promoter CpG island
(Y. Du and S.H., in preparation). While the importance of genetic
mutations in cancer has long been recognized, the appreciation of
epigenetic inactivation is more recent (Jones and Laird, 1999;
Baylin and Herman, 2000; Eng et al, 2000). Recent studies have
firmly established methylation as one potential hit in a modified
Knudson’s two-hit model (Jones and Laird, 1999). Thus, RIZ1
gene silencing and LOH could together achieve the two-hit
inactivation of RIZ1. 
Human HCC, colon carcinoma, and breast cancers are known to
show LOH of 1p36 markers (Genuardi et al, 1989; Simon et al,
1991; Bardi et al, 1993; Kuroki et al, 1995). The minimal deleted
regions in these cancers include the RIZ locus. Our results here
confirm previous findings and directly demonstrate LOH of RIZ in
these cancers. To the best of our knowledge, there has been no
published report of LOH of 1p36 in stomach cancers. Here, we
detected low frequency of LOH of RIZ in stomach cancer (12% in
66 stomach cancer cases), which indicates either a minor role of
RIZ or 1p36 in this cancer or simply background rate chromo-
somal instabilities. 
The preferential loss of the Pro704+ allele in HCC suggests that
this allele may be a stronger suppressor allele than the Pro704-
allele. This notion would predict that individuals homozygous for
the Pro704- allele would be more susceptible to tumour formation
than those who are homozygous or heterozygous for the Pro704+
allele. At least two observations are consistent with this prediction.
First, our data did indicate a trend toward enrichment of the
Pro704- allele in Korean HCC patients (Table 4). 
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Table 5 Distribution of the Pro704-deletion polymorphism 
P704+ hom P704- hom Het Total 
Caucasian patients (P704+frequency = 0.43)a
US HCC 3 2 5 10 
US colon cancer 12 22 26 60 
US breast cancer 3 16 22 41 
US stomach cancer 9 9 21 39 
Total 27 (17.5%) 49 (32.5%) 74 (50%) 150 
Caucasian normal (P704+frequency = 0.37) 
Canadian 1 6 6 13 
Belgian 5 12 13 30 
Total 6 (14%) 18 (41.9) 19 (44.2%) 43 
Asian patients (P704+frequency = 0.61)a
C. HCCb 34 11 53 98 
K. HCC 11 7 21 39 
K. breast cancer 16 3 21 40 
K. colon cancer 14 11 21 46 
K. stomach cancer 34 7 45 86 
Total 109 (34.9%) 39 (13.1%) 161 (51.9%) 309 
aGenomic DNAs of normal tissues from cancer patients were used for the study. bC = Chinese; K = Korean. Second, the Pro704- allele is more enriched in Caucasian popu-
lation compared to Asian population, which correlates with the
known higher tumour incidence of Caucasians (see below).
Nonetheless, this prediction needs to be further verified by future
carefully controlled epidemiological studies. Also, the role of the
Pro704 deletion polymorphism in non-HCC cancers will need to
be further determined. 
Our data show that the Pro704+ allele of RIZ is significantly more
common in cancer patients of Korean and Chinese than in those of
Caucasian. Because we did not observe significant difference
between cancer patients and normal individuals of Caucasian origin
in the distribution of the Pro704+ allele, we conclude that the allele
frequency observed in Asian cancer patients is largely representat-
ive of normal populations. In turn, we conclude that the Pro704+
allele is more common in Asian than Caucasian populations. This
conclusion reveals an interesting link between a stronger suppressor
allele and lower tumour incidence: Korean and Chinese have long
been noted to have lower overall tumour incidence than Caucasians
(Landis et al, 1999; Registry, 1995). Although it remains an
unresolved issue whether genetic factors may exist to explain the
disparity in tumour incidence between different racial groups, our
data here suggests that gene polymorphisms can not be excluded. 
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